One analyst isn’t sure Pfizer can afford to be behind in both immuno-oncology and Alzheimer’s. And while his peers have suggested bulking up in I-O to solve that issue, he has a different idea.
BMO’s Alex Arfaei sees “strong strategic rationale” for a merger between Pfizer and neuro specialist Bioegen, he wrote in a Monday note to clients, arguing that a tie-up between the two would make “more sense” than a Pfizer buy of I-O hotshot Bristol-Myers Squibb that’s been rumored for months.
Leave a Comment